{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:39:53Z","timestamp":1790170793494,"version":"4.1.0"},"reference-count":37,"publisher":"American Chemical Society (ACS)","issue":"1","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccbyncnd_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100011272","name":"FP7 Health","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody fragment F8-mediated interleukin 10 (IL10) delivery is a novel treatment for rheumatoid arthritis (RA). F8 binds to the extra-domain-A of fibronectin (ED-A). In this study, in vivo biodistribution and arthritis targeting of radiolabeled F8-IL10 were investigated in RA patients, followed by further animal studies. Therefore, three RA patients (DAS28 &amp;gt; 3.2) received 0.4 mg of 30\u201374 megabecquerel [124I]I\u2013F8\u2013IL10 for PET-CT and blood sampling. In visually identified PET-positive joints, target-to-background was calculated. Healthy mice, rats, and arthritic rats were injected with iodinated F8-IL10 or KSF-IL10 control antibody. Various organs were excised, weighed, and counted for radioactivity. Tissue sections were stained for fibronectin ED-A. In RA patients, [124I]I\u2013F8\u2013IL10 was cleared rapidly from the circulation with less than 1% present in blood after 5 min. PET-CT showed targeting in 38 joints (11\u201315 per patient) and high uptake in the liver and spleen. Mean target-to-background ratios of PET-positive joints were 2.5 \u00b1 1.2, 1.5 times higher for clinically active than clinically silent joints. Biodistribution of radioiodinated F8-IL10 in healthy mice showed no effect of the radioiodination method. [124I]I\u2013F8\u2013IL10 joint uptake was also demonstrated in arthritic rats, \u223c14-fold higher than that of the control antibody [124I]I-KSF-IL10 (p &amp;lt; 0.001). Interestingly, liver and spleen uptake were twice as high in arthritic than in healthy rats and were related to increased (\u223c7\u00d7) fibronectin ED-A expression in these tissues. In conclusion, [124I]I\u2013F8\u2013IL10 uptake was observed in arthritic joints in RA patients holding promise for visualization of inflamed joints by PET-CT imaging and therapeutic targeting. Patient observations and, subsequently, arthritic animal studies pointed to awareness of increased [124I]I\u2013F8\u2013IL10 uptake in the liver and spleen associated with moderate systemic inflammation. This translational study demonstrated the value of in vivo biodistribution and PET-CT-guided imaging in development of new and potential antirheumatic drugs\u2019.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.8b00982","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T15:00:12Z","timestamp":1544799612000},"page":"273-281","source":"Crossref","is-referenced-by-count":29,"title":["F8-IL10: A New Potential Antirheumatic Drug Evaluated\nby a PET-Guided Translational Approach"],"prefix":"10.1021","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2155-4929","authenticated-orcid":true,"given":"Stefan T.G.","family":"Bruijnen","sequence":"first","affiliation":[{"name":"Amsterdam University Medical Center, Location VU University Medical Center , , ,","place":["Amsterdam, The Netherlands, 1007 MB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durga M.S.H.","family":"Chandrupatla","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center, Location VU University Medical Center , , ,","place":["Amsterdam, The Netherlands, 1007 MB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Giovanonni","sequence":"additional","affiliation":[{"name":"Philogen S.p.A. , ,","place":["Siena, Italy, 53100"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Neri","sequence":"additional","affiliation":[{"name":"ETH Zu\u0308rich , , ,","place":["Zu\u0308rich, Switzerland, 8092"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle J.","family":"Vugts","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center, location VU University Medical Center , , ,","place":["Amsterdam, The Netherlands, 1007 MB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc C.","family":"Huisman","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center, location VU University Medical Center , , ,","place":["Amsterdam, The Netherlands, 1007 MB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto S.","family":"Hoekstra","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center, location VU University Medical Center , , ,","place":["Amsterdam, The Netherlands, 1007 MB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene\u0301 J.P.","family":"Musters","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center, location VU University Medical Center , , ,","place":["Amsterdam, The Netherlands, 1007 MB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Lammertsma","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center, location VU University Medical Center , , ,","place":["Amsterdam, The Netherlands, 1007 MB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guus A.M.S.","family":"van Dongen","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center, location VU University Medical Center , , ,","place":["Amsterdam, The Netherlands, 1007 MB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Jansen","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center, Location VU University Medical Center , , ,","place":["Amsterdam, The Netherlands, 1007 MB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla F.M.","family":"Molthoff","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center, location VU University Medical Center , , ,","place":["Amsterdam, The Netherlands, 1007 MB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conny J.","family":"van der Laken","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center, Location VU University Medical Center , , ,","place":["Amsterdam, The Netherlands, 1007 MB"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"issue":"23","key":"2026090308175755400_cit1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2026090308175755400_cit2","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of\nrheumatoid arthritis with synthetic and biological disease-modifying\nantirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"2026090308175755400_cit3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of\nanti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"2026090308175755400_cit4","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid\narthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"2026090308175755400_cit5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ncprheum0020","article-title":"Cytokine networks--towards\nnew therapies for rheumatoid\narthritis","volume":"1","author":"McInnes","year":"2005","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"2026090308175755400_cit6","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood-2008-06-160416","article-title":"Expression of the oncofetal\nED-B \u2013 containing fibronectin isoform in hematologic tumors\nenables ED-B \u2013 targeted 131 I-L19SIP radioimmunotherapy in\nHodgkin lymphoma patients","volume":"113","author":"Sauer","year":"2009","journal-title":"Blood."},{"key":"2026090308175755400_cit7","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1200\/JCO.2004.11.035","article-title":"Phase I clinical trial of the immunocytokine EMD 273063\nin melanoma patients","volume":"22","author":"King","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"2026090308175755400_cit8","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1158\/1078-0432.CCR-07-5041","article-title":"Antibody-mediated\ndelivery\nof interleukin-2 to the stroma of breast cancer strongly enhances\nthe potency of chemotherapy","volume":"14","author":"Ma\u030arlind","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2026090308175755400_cit9","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/sj.bjc.6605832","article-title":"Combination\nof Temozolomide with immunocytokine F16-IL2\nfor the treatment of glioblastoma","volume":"103","author":"Pedretti","year":"2010","journal-title":"Br. J. Cancer"},{"key":"2026090308175755400_cit10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1126\/science.aal3535","article-title":"Anti-inflammatory\neffect of IL-10 mediated by metabolic reprogramming of macrophages","volume":"356","author":"Ip","year":"2017","journal-title":"Science"},{"key":"2026090308175755400_cit11","doi-asserted-by":"publisher","first-page":"8686","DOI":"10.1073\/pnas.0500419102","article-title":"The primary\nmechanism of the IL-10-regulated antiinflammatory response is to selectively\ninhibit transcription","volume":"102","author":"Murray","year":"2005","journal-title":"Proc. Natl. Acad. Sci.\nU. S. A."},{"issue":"9","key":"2026090308175755400_cit12","first-page":"S170","article-title":"RHUIL-10\n(TENOVIL) plus methotrexate (MTX) in active rheumatoid arthritis (RA):\nA phase I\/II study","volume":"42","author":"Weinblatt","year":"1999","journal-title":"Arthritis Rheum."},{"key":"2026090308175755400_cit13","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1186\/ar3744","article-title":"Anti-citrullinated\nfibronectin antibodies in rheumatoid arthritis are associated with\nhuman leukocyte antigen-DRB1 shared epitope alleles","volume":"14","author":"van Beers","year":"2012","journal-title":"Arthritis Research & Therapy"},{"key":"2026090308175755400_cit14","doi-asserted-by":"publisher","first-page":"10948","DOI":"10.1158\/0008-5472.CAN-07-1436","article-title":"The extra-domain\nA of fibronectin is a vascular marker of solid tumors and metastases","volume":"67","author":"Rybak","year":"2007","journal-title":"Cancer Res."},{"key":"2026090308175755400_cit15","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1002\/ijc.23408","article-title":"A high-affinity human\nmonoclonal antibody specific to the alternatively spliced EDA domain\nof fibronectin efficiently targets tumor neo-vasculature in vivo","volume":"122","author":"Villa","year":"2008","journal-title":"Int. J. Cancer"},{"key":"2026090308175755400_cit16","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1186\/ar2814","article-title":"Preclinical characterization\nof DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which\ninhibits the progression of collagen-induced arthritis","volume":"11","author":"Schwager","year":"2009","journal-title":"Arthritis Research & Therapy"},{"key":"2026090308175755400_cit17","first-page":"666","article-title":"A phase IB clinical trial with dekavil (F8-Il10), An\nimmunoregulatory armed antibody for the treatment of rheumatoid arthritis,\nused in combination with methotrexate","volume":"16","author":"Galeazzi","year":"2014","journal-title":"Israel\nMedical Association Journal"},{"key":"2026090308175755400_cit18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13402-014-0194-4","article-title":"Molecular imaging of targeted therapies\nwith positron emission tomography: the visualization of personalized\ncancer care","volume":"38","author":"Mammatas","year":"2015","journal-title":"Cell. Oncol."},{"issue":"5","key":"2026090308175755400_cit19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jamaoncol.2016.5084","article-title":"Making Molecular\nImaging a Clinical Tool for Precision Oncology: A Review","volume":"3","author":"Mankoff","year":"2017","journal-title":"JAMA Oncol."},{"issue":"4","key":"2026090308175755400_cit20","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1158\/0008-5472.CAN-04-2008","article-title":"Quantitative immuno-positron\nemission tomography imaging of HER2-positive tumor xenografts with\nan iodine-124 labeled anti-HER2 diabody","volume":"65","author":"Robinson","year":"2005","journal-title":"Cancer\nRes."},{"key":"2026090308175755400_cit21","first-page":"18","article-title":"89Zr-immuno-PET for imaging of long circulating drugs and disease\ntargets: Why, how and when to be applied?","volume":"59","author":"Van Dongen","year":"2015","journal-title":"Quarterly\nJournal of Nuclear Medicine and Molecular Imaging"},{"key":"2026090308175755400_cit22","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1634\/theoncologist.12-12-1379","article-title":"Immuno-PET: A Navigator in Monoclonal\nAntibody Development and Applications","volume":"12","author":"van Dongen","year":"2007","journal-title":"Oncologist"},{"key":"2026090308175755400_cit23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The\nAmerican Rheumatism Association 1987 revised\ncriteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"2026090308175755400_cit24","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1155\/2015\/509295","article-title":"Sustained macrophage\ninfiltration upon multiple intra-articular injections: An improved\nrat model of rheumatoid arthritis for PET guided therapy evaluation","volume":"2015","author":"Chandrupatla","year":"2015","journal-title":"BioMed Res. Int."},{"key":"2026090308175755400_cit25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8092781","article-title":"Imaging and Methotrexate Response Monitoring\nof Systemic Inflammation in Arthritic Rats Employing the Macrophage\nPET Tracer [(18)F]Fluoro-PEG-Folate","volume":"2018","author":"Chandrupatla","year":"2018","journal-title":"Contrast\nMedia Mol. Imaging"},{"issue":"1","key":"2026090308175755400_cit26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","article-title":"Determination\nof the immunoreactive fraction of radiolabeled\nmonoclonal antibodies by linear extrapolation to binding at infinite\nantigen excess","volume":"72","author":"Lindmo","year":"1984","journal-title":"J. Immunol. Methods"},{"key":"2026090308175755400_cit27","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2967\/jnumed.111.101006","article-title":"Radioimmunotherapy with Radretumab in Patients\nwith Relapsed Hematologic Malignancies","volume":"53","author":"Erba","year":"2012","journal-title":"J. Nucl.\nMed."},{"key":"2026090308175755400_cit28","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00259-009-1096-y","article-title":"124I-L19-SIP for immuno-PET\nimaging of tumour vasculature and guidance of131I-L19-SIP radioimmunotherapy","volume":"36","author":"Tijink","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"2026090308175755400_cit29","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1039\/c0ib00099j","article-title":"Antibody-based targeting\nof interferon-alpha to the tumor neovasculature: a critical evaluation","volume":"3","author":"Frey","year":"2011","journal-title":"Integr Biol. (Camb)."},{"issue":"2","key":"2026090308175755400_cit30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure\nguidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026090308175755400_cit31","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1007\/s00259-008-0874-2","article-title":"The Netherlands protocol for standardisation\nand quantification of FDG whole body PET studies in multi-centre trials","volume":"35","author":"Boellaard","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026090308175755400_cit32","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00259-004-1566-1","article-title":"Effects\nof ROI definition and reconstruction method\non quantitative outcome and applicability in a response monitoring\ntrial","volume":"32","author":"Krak","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026090308175755400_cit33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2967\/jnumed.111.093443","article-title":"Impact of\nthe definition of peak\nstandardized uptake value on quantification of treatment response","volume":"53","author":"Vanderhoek","year":"2012","journal-title":"J. Nucl. Med."},{"key":"2026090308175755400_cit34","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.18632\/oncotarget.6169","article-title":"Multifactorial resistance to aminopeptidase\ninhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation\nof carboxylesterase 1, drug sequestration in lipid droplets and pro-survival\nactivation ERK\/Akt\/mTOR","volume":"7","author":"Verbrugge","year":"2016","journal-title":"Oncotarget"},{"key":"2026090308175755400_cit35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/annrheumdis-2017-eular.4840","article-title":"OP0099 Safety, tolerability\nand initial signs of efficacy of the fully human immunocytokine DEKAVIL\n(F8IL10): a novel therapeutic approach for rheumatoid arthritis","volume":"76","author":"Galeazzi","year":"2017","journal-title":"Ann. Rheum Dis."},{"issue":"3","key":"2026090308175755400_cit36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.nucmedbio.2003.10.010","article-title":"Modification\nof low-density lipoprotein\nby different radioiodination methods","volume":"31","author":"Sobal","year":"2004","journal-title":"Nucl.\nMed. Biol."},{"key":"2026090308175755400_cit37","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s00259-015-3025-6","article-title":"Tumour\ntargeting and radiation dose of radioimmunotherapy\nwith 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab\nimmuno-PET: impact of preloading with unlabelled rituximab","volume":"42","author":"Muylle","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.8b00982","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/16\/1\/273\/67235692\/acs.molpharmaceut.8b00982.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/16\/1\/273\/67235692\/acs.molpharmaceut.8b00982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:18:03Z","timestamp":1788437883000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/16\/1\/273\/974347\/F8-IL10-A-New-Potential-Antirheumatic-Drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,14]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12,14]]},"published-print":{"date-parts":[[2019,1,7]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00982","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,14]]}}}